Supplementary Figure 2 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

• Genomic alterations were revealed in circulating tumor DNA, highlighting changes during disease progression.
• Targeted sequencing identified significant mutations in ERBB2/HER2 in patients with metastatic urothelial cancer.
• Whole-genome sequencing provided comprehensive insights into both ctDNA and metachronous tissues' genomic profiles.
• The study emphasizes the potential for ctDNA testing in monitoring tumor evolution and treatment response.